指南与共识抗栓抗凝管理肝肾功能剂量调整药物不良反应与药物警戒

新诊断房颤患者口服抗凝治疗指南的实施情况

Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation.
指南 / 共识 · Br J Clin Pharmacol · 2021-05-29

AIMS: Oral anticoagulants (OACs) are considered the mainstay in preventing stroke in atrial fibrillation (AF). OAC treatment remains suboptimal among AF patients, even after the introduction of direct oral anticoagulants (DOACs).…

要点

  • 高危房颤患者3个月OAC治疗率逐年上升,2018–2019达61.7%。
  • DOAC在处方OAC中占比从2014–2015的51.3%升至2018–2019的95.1%。
  • 肾功能受损和吸烟者OAC启动可能性较低,CHA2DS2-VASc越高、HAS-BLED越低越可能启动。

核心结论

  • 高危房颤患者OAC治疗率虽因DOAC使用扩大而上升,但治疗覆盖范围仍远未达最优。

主要发现

  • 3个月累积OAC治疗率在2014–2015、2016–2017、2018–2019分别为46.9%(95%CI 46.1–47.7%)、54.9%(54.1–55.6%)和61.7%(60.9–62.4%)。
  • DOAC占处方OAC的比例从2014–2015的51.3%升至2018–2019的95.1%。
  • 多因素分析显示OAC启动可能性随年份和社会经济阶层升高而增加,女性、犹太人、他汀使用者和曾接受结直肠癌筛查者更可能启动,吸烟者和肾功能受损者更不可能启动。
  • OAC启动可能性随CHA2DS2-VASc评分升高而增加,随HAS-BLED评分升高而降低。

临床怎么用

  • 临床应关注高危房颤患者OAC治疗率的持续提升,尤其需关注肾功能受损和吸烟人群的启动不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Oral anticoagulants (OACs) are considered the mainstay in preventing stroke in atrial fibrillation (AF). OAC treatment remains suboptimal among AF patients, even after the introduction of direct oral anticoagulants (DOACs). We aimed to assess trends overtime and current implementation of OAC treatment guidelines in AF, using a large dataset of real world data from Israel. METHODS: This is a retrospective cohort study that includes all adult members of Clalit Health Services, the largest healthcare provider in Israel, with newly diagnosed nonvalvular AF between January 2014 and December 2019 with CHA2 DS2 -VASc score ≥2. OAC treatment rates were calculated and multivariate regression models were used to identify predictors of OACs initiation. RESULTS: Overall, 46 531 patients were included in the study. The 3-months cumulative OAC treatment rates increased consistently over the years: 46.9% (95% confidence interval, 46.1-47.7%), 54.9% (54.1-55.6%) and 61.7% (60.9-62.4%) during 2014-2015, 2016-2017 and 2018-2019, respectively. DOACs constituted 51.3% of prescribed OACs in 2014-2015 and increased to 95.1% during 2018-2019. On multivariate analyses, the likelihood of OACs initiation among AF patients increased across the years and across higher socioeconomic classes, and was more likely among females, Jews, statins users and patients previously screened for colorectal cancer, but less likely among smokers and patients with impaired renal function. The likelihood of treatment increased with higher CHA2 DS2 -VASc score and decreased with higher HAS-BLED score. CONCLUSION: Despite the increasing OAC treatment rates among high-risk AF patients, mainly attributed to the expanding DOAC use, OAC treatment scope is still far from optimal.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Arbel A, Abu-Ful Z, Preis M, et al. Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. Br J Clin Pharmacol. 2021. PMID: 33982796. doi:10.1111/bcp.14899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。